Nanobac Announces Results of Pre-IND Meeting with FDA.

TAMPA, Fla. -- Nanobac Pharmaceuticals, Inc. (OTCBB:NNBP) "Nanobac" or "the Company" announces the results of a Pre-IND meeting with the FDA on January 19, 2007 to discuss specific details of the plan for developing a treatment for patients with chronic prostatitis, referred to as CP/CPPS, and to discuss the content of the initial IND required to support clinical evaluation.

Nanobac Pharmaceuticals, Inc. and FDA representatives were in agreement on the general approach to the development program and steps leading to an IND submission and the start of clinical trials. "We view this meeting as a positive step in building a collaborative relationship with the FDA and believe the path set out by the FDA will result in meaningful data on the use of our combination therapies against prostatitis," stated Dr. Benedict Maniscalco, Co-Chair and Chief Medical Officer for Nanobac Pharmaceuticals.

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) also referred to as category III prostatitis, is defined by pelvic pain associated with ejaculatory and/or urinating pain/discomfort lasting longer than 3 months. In the United States, more than 2 million men per year will visit their physician for prostatitis.

About Nanobac Pharmaceuticals: Nanobac Pharmaceuticals, Inc. is dedicated to the discovery and development of products and services to improve human health through the detection and treatment of calcifying nanoparticles (CNPs), formerly known as nanobacteria. The company's pioneering research is establishing the pathogenic role of CNPs in soft tissue calcification, particularly in coronary artery, prostate and vascular disease.

Nanobac's drug discovery and development is focused on new and existing compounds that effectively inhibit, destroy or neutralize CNPs. Nanobac manufactures In Vitro Diagnostic (IVD) kits and reagents for detecting calcifying nanoparticles. IVD products include a line of assays, proprietary antibodies and reagents for uniquely recognizing CNPs. Nanobac's BioAnalytical Services works with biopharmaceutical partners to develop and apply methods for avoiding, detecting, and inactivating or eliminating CNPs from raw materials.

Nanobac Pharmaceuticals, Inc. is headquartered in Tampa, Florida. For more information, visit our website at: http://www.nanobac.com.

Investors are cautioned that certain statements in this document, some statements in periodic press releases and some oral statements of Nanobac Pharmaceuticals, Inc. officials are "Forward-Looking Statements" within the meaning of the Private Securities Litigation Reform Act of 1995 (the "Act"). Forward-Looking statements include statements which are predictive in nature, which depend upon or refer to future events or conditions, which include words such as "believes," "anticipates," "intends," "plans," "expects," and similar expressions. In addition, any statements concerning future financial performance (including future revenues, earnings or growth rates), ongoing business strategies or prospects, and possible future Nanobac Pharmaceuticals, Inc. actions, which may be provided by management, are also forward-looking statements as defined by the Act. Forward-Looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance or achievements of the Company to materially differ from any future results, performance or achievements expressed or implied by such forward-looking statements and to vary significantly from reporting period to reporting period. Although management believes that the assumptions will, in fact, prove to be correct or that actual future results will not be different from the expectations expressed in this report. These statements are not guarantees of future performance and Nanobac Pharmaceuticals, Inc. has no specific intention to update these statements.